Literature DB >> 17413687

Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.

Fernando A Frankel1, Cédric F Invernizzi, Maureen Oliveira, Mark A Wainberg.   

Abstract

OBJECTIVES: To determine the underlying biochemical mechanisms responsible for the diminished viral replicative capacity associated with K65R/M184V-containing viruses.
METHODS: We studied the efficiency of (-)ssDNA synthesis by recombinant wild-type and mutated HIV-1 reverse transcriptases in cell-free assays. In addition, we determined susceptibility levels to nucleoside analog reverse transcriptase inhibitors (NRTIs) both in cell-free and cell culture assays.
RESULTS: We observed that the K65R/M184V mutations in reverse transcriptase caused reductions in the efficiency of initiation of (-)ssDNA synthesis by increasing pausing at positions +3 and +5 as well as diminished RNA usage. These findings were confirmed in cell culture data using MT-4 cells and cord blood mononuclear cells.
CONCLUSIONS: The simultaneous presence of K65R and M184V in reverse transcriptase has a negative impact with regard to the efficiency of initiation of (-)ssDNA synthesis and RNA usage, that exceeds the effect of either mutation on its own. These mechanisms, among others, are responsible for the diminished viral replicative capacity observed in tissue culture when K65R/M184V-containing viruses are studied.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413687     DOI: 10.1097/QAD.0b013e3280187505

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Authors:  Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

2.  Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Peter K Quashie; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

3.  A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Authors:  Antonio J Acosta-Hoyos; Suzanne E Matsuura; Peter R Meyer; Walter A Scott
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Authors:  Dara A Lehman; Jared M Baeten; Connor O McCoy; Julie F Weis; Dylan Peterson; Gerald Mbara; Deborah Donnell; Katherine K Thomas; Craig W Hendrix; Mark A Marzinke; Lisa Frenkel; Patrick Ndase; Nelly R Mugo; Connie Celum; Julie Overbaugh; Frederick A Matsen
Journal:  J Infect Dis       Date:  2015-01-13       Impact factor: 5.226

5.  Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

Authors:  Alberto M La Rosa; Linda J Harrison; Babafemi Taiwo; Carole L Wallis; Lu Zheng; Peter Kim; Nagalingeswaran Kumarasamy; Mina C Hosseinipour; Bernadette Jarocki; John W Mellors; Ann C Collier
Journal:  Lancet HIV       Date:  2016-04-18       Impact factor: 12.767

6.  Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

8.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

9.  Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.

Authors:  Julie F Weis; Jared M Baeten; Connor O McCoy; Chris Warth; Deborah Donnell; Katherine K Thomas; Craig W Hendrix; Mark A Marzinke; Nelly Mugo; Frederick A Matsen; Connie Celum; Dara A Lehman
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

10.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.